Transcription of MULTIPLE MYELOMA (MM) - Celgene
{{id}} {{{paragraph}}}
Example: marketing
MULTIPLE MYELOMA (MM) - Celgene
Area of Research Phase 1 Phase 2 Phase 3 Post-Approval Research MULTIPLE MYELOMA (MM). REVLIMID (lenalidomide) . Relapsed/refractory .. Newly diagnosed .. Maintenance .. POMALYST /IMNOVID (US/EU).. (pomalidomide) Relapsed/refractory .. THALOMID /Thalidomide Celgene . (US/EU) (thalidomide) Newly diagnosed .. IMFINZI (durvalumab) a Relapsed/refractory, newly diagnosed* .. CC-122 .. BCMA CAR T (bb2121) b Relapsed/refractory .. BCMA CAR T (bb21217) b .. CC-220 Relapsed/refractory .. Citarinostat (ACY-241) Relapsed/refractory .. CC-92480 .. MYELODYSPLASTIC SYNDROMES (MDS). VIDAZA (azacitidine for injection) .. REVLIMID (lenalidomide).
Area of Research Phase 1 Phase 2 Phase 3 Post-Approval Research C C F P- esear C- C- T T appr LYMPHOMA REVLIMID® (lenalidomide) Mantle cell lymphoma: Relapsed/refractory . . . . . . . . . . Diffuse large B-cell lymphoma (ABC subtype): First-line .
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: